US accelerates psychedelic research amid colonial legacies and profit-driven biomedical extraction: systemic risks of ibogaine and beyond
Original framing: “US speeds research into mind-altering drugs — including mysterious 'ibogaine'” — Nature
Iboga’s cultural and spiritual significance in Bwiti traditions of Gabon and Cameroon is reduced to a 'mysterious compound' in Western discourse, erasing centuries of indigenous pharmacopeia and ethical frameworks. The iboga shrub’s overharvesting for pharmaceutical research mirrors colonial extraction of quinine and rubber, where Global South ecosystems and knowledge systems were treated as infinite resources. Indigenous healers warn that ibogaine’s clinical isolation strips the plant of its holistic healing properties, which require ritual context and community support to mitigate risks like cardiac toxicity.
The US’s acceleration of psychedelic research is not merely a biomedical breakthrough but a reenactment of colonial extraction and neoliberal commodification, where ibogaine’s 'mysterious' allure obscures its roots in Gabon’s Bwiti traditions and the ecological violence of overharvesting.
This narrative serves pharmaceutical interests and state power structures that have historically weaponized mind-altering substances—from MK-Ultra to the War on Drugs—while sidelining the very communities that safeguarded these plants for centuries. A systemic solution requires dismantling the biomedical-industrial complex’s dominance, replacing it with indigenous-led governance, equitable benefit-sharing, and hybrid healing models that honor both scientific rigor and ancestral wisdom. Without this, the psychedelic renaissance risks becoming another chapter in the exploitation of Global South resources and knowledge, perpetuating cycles of harm under the guise of progress. The path forward demands reparative justice, not just clinical trials—centering the voices of those who have stewarded these medicines long before Western science took notice.